An oral acromegaly treatment that’s 24 hours, one DOSE.


Crinetics is recruiting patients to participate in a study of ONCE-DAILY paltusotine for the treatment of acromegaly.

PATHFNDR-1 is a Phase 3, randomized, placebo-controlled, multi-center study to evaluate the safety and efficacy of paltusotine, a nonpeptide, orally bioavailable somatostatin receptor 2 (SST2) agonist taken once daily. In Phase 2 studies, paltusotine was shown to maintain GH and IGF-1 levels in patients with acromegaly who were previously on octreotide LAR or lanreotide depot monotherapy.

If you have acromegaly patients interested in a ONCE-DAILY, ORAL therapy, please refer them to the study intake page to check eligibility and to be contacted by the study team.

Go To Intake Page

To be eligible, patients must:
• Be 18 years of age or older
• Have medically stable, confirmed-active acromegaly
• Be on an approved, stable dose of long-acting octreotide or lanreotide, for at least 12 weeks prior to screening

Key exclusion criteria:
• Treatment-naïve or treatment-withdrawn acromegaly subjects
• History of pituitary radiation therapy
• Subjects with adrenal insufficiency who are not receiving adequate adrenal replacement therapy at the time of screening, as determined by the Investigator
• Pituitary adenoma that might require immediate surgical treatment or pituitary carcinoma

An oral acromegaly treatment that’s 24 hours, one DOSE.


Crinetics is recruiting patients to participate in a study of ONCE-DAILY paltusotine for the treatment of acromegaly.

PATHFNDR-1 is a Phase 3, randomized, placebo-controlled, multi-center study to evaluate the safety and efficacy of paltusotine, a nonpeptide, orally bioavailable somatostatin receptor 2 (SST2) agonist taken once daily. In Phase 2 studies, paltusotine was shown to maintain GH and IGF-1 levels in patients with acromegaly who were previously on octreotide LAR or lanreotide depot monotherapy.

If you have acromegaly patients interested in a ONCE-DAILY, ORAL therapy, please refer them to the study intake page to check eligibility and to be contacted by the study team.

To be eligible, patients must:
• Be 18 years of age or older
• Have medically stable, confirmed-active acromegaly
• Be on an approved, stable dose of long-acting octreotide or lanreotide, for at least 12 weeks prior to screening

Key exclusion criteria:
• Treatment-naïve or treatment-withdrawn acromegaly subjects
• History of pituitary radiation therapy
• Subjects with adrenal insufficiency who are not receiving adequate adrenal replacement therapy at the time of screening, as determined by the Investigator
• Pituitary adenoma that might require immediate surgical treatment or pituitary carcinoma

Visit the Trial Page on clinicaltrials.gov


Visit the ClinicalTrial Page on clinicaltrials.gov


Review the study summary, outcome measures, inclusion/exclusion criteria and more for the Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-1).

Visit clinicaltrials.gov

Share This Information


The PATHFNDR-1 brochure answers common questions patients have when considering enrollment in a study. You can download it here and forward it to any of your patients who express interest in learning more.

Questions?


For questions about the PATHFNDR-1 study, contact Chris Postiglione, Senior Director of Medical Affairs at Crinetics at cpostiglione@crinetics.com.

Share This Information


The PATHFNDR-1 brochure answers common questions patients have when considering enrollment in a study. You can download it here and forward it to any of your patients who express interest in learning more.

Download PATHFNDR-1 Brochure

Questions?


For questions about the PATHFNDR-1 study, contact Chris Postiglione, Senior Director of Medical Affairs at Crinetics at cpostiglione@crinetics.com.